NAA11

Summary

NAA11 (N-alpha-acetyltransferase 11, NatA catalytic subunit, HGNC:28125) is a protein-coding gene on chromosome 4q21.21, encoding N-alpha-acetyltransferase 11 (Q9BSU3). Displays alpha (N-terminal) acetyltransferase activity.

Enables protein-N-terminal amino-acid acetyltransferase activity. Involved in N-terminal protein amino acid acetylation. Located in several cellular components, including Golgi apparatus; microtubule organizing center; and nucleoplasm. Part of NatA complex.

Source: NCBI Gene 84779 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 34 total
• MANE Select transcript: NM_032693

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28125
Approved symbol	NAA11
Name	N-alpha-acetyltransferase 11, NatA catalytic subunit
Location	4q21.21
Locus type	gene with protein product
Status	Approved
Aliases	ARD2, hARD2
Ensembl gene	ENSG00000156269
Ensembl biotype	protein_coding
OMIM	619432
Entrez	84779

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 1 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000286794, ENST00000511542, ENST00000513733

RefSeq mRNA: 1 — MANE Select: NM_032693 NM_032693

CCDS: CCDS47084

Canonical transcript exons

ENST00000286794 — 2 exons

Exon	Start	End
ENSE00001025537	79325176	79326061
ENSE00001073095	79316647	79317791

Expression profiles

Bgee: expression breadth ubiquitous, 119 present calls, max score 91.33.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.1861 / max 128.7892, expressed in 84 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52736	1.1861	84

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	91.33	gold quality
oocyte	CL:0000023	90.83	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.22	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.87	gold quality
right testis	UBERON:0004534	72.58	gold quality
left testis	UBERON:0004533	72.45	gold quality
testis	UBERON:0000473	72.02	gold quality
tibialis anterior	UBERON:0001385	67.51	silver quality
placenta	UBERON:0001987	67.32	gold quality
sperm	CL:0000019	66.24	gold quality
male germ cell	CL:0000015	65.04	gold quality
pancreatic ductal cell	CL:0002079	65.02	silver quality
popliteal artery	UBERON:0002250	61.45	gold quality
tibial artery	UBERON:0007610	61.37	gold quality
adult organism	UBERON:0007023	60.85	gold quality
diaphragm	UBERON:0001103	58.90	gold quality
tibial nerve	UBERON:0001323	58.53	gold quality
calcaneal tendon	UBERON:0003701	58.42	gold quality
ileal mucosa	UBERON:0000331	56.95	silver quality
deltoid	UBERON:0001476	56.33	gold quality
aorta	UBERON:0000947	54.87	gold quality
descending thoracic aorta	UBERON:0002345	52.90	gold quality
upper leg skin	UBERON:0004262	52.30	silver quality
mucosa of stomach	UBERON:0001199	52.09	gold quality
epithelial cell of pancreas	CL:0000083	52.07	silver quality
lower esophagus muscularis layer	UBERON:0035833	51.99	gold quality
lower esophagus	UBERON:0013473	51.88	gold quality
tendon	UBERON:0000043	51.50	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	51.20	gold quality
body of uterus	UBERON:0009853	50.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

39 targeting NAA11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-3919	99.87	69.45	2489
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-516A-3P	99.46	67.96	1378
HSA-MIR-516B-3P	99.46	67.96	1378
HSA-MIR-7162-5P	99.46	68.08	1368
HSA-MIR-4762-3P	99.43	69.72	2363
HSA-MIR-5695	99.41	67.48	1047
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-4751	98.80	64.95	525
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-6887-5P	98.56	68.49	1295
HSA-MIR-6795-5P	98.52	68.51	1277
HSA-MIR-6730-5P	98.03	68.12	1299
HSA-MIR-510-5P	97.66	65.82	916
HSA-MIR-2278	97.30	66.19	1130
HSA-MIR-148B-5P	97.29	66.30	992

Literature-anchored findings (GeneRIF, showing 5)

• hARD2 (MGC10646) is a novel human protein N-alpha acetyltransferase (PMID:16638120)
• hARD2, an N-alpha-acetyltransferase has 81 % sequence identity to hARD1. Its gene may originate from a eutherian-mammal-specific retrotransposition event. hARD2-NATH complexes may be responsible for protein N-alpha-acetylation in human cells. (PMID:16638120)
• LOH in genes around D4S2964, including ARD1B and SEPT11 may play an important role in hepatocellular carcinoma development and progression (PMID:20419844)
• NAA11 expression is tissue-specific and is epigenetically regulated by DNA methylation. (PMID:22048246)
• ARD1 protein was observed at 61.0% (50/82), 54.7% (87/159), 37.9% (25/66), 36.8% (7/19) in IDC, fibroadenoma, hyperplasia, and inflammation, respectively. (PMID:22292636)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
caenorhabditis_elegans		WBGENE00000923

Paralogs (4): NAA10 (ENSG00000102030), NAA50 (ENSG00000121579), NAA30 (ENSG00000139977), NAA20 (ENSG00000173418)

Protein

Protein identifiers

N-alpha-acetyltransferase 11 — Q9BSU3 (reviewed: Q9BSU3)

Alternative names: N-terminal acetyltransferase complex ARD1 subunit homolog B, NatA catalytic subunit Naa11

All UniProt accessions (2): Q9BSU3, H0Y8T0

UniProt curated annotations — full annotation on UniProt →

Function. Displays alpha (N-terminal) acetyltransferase activity. Proposed alternative catalytic subunit of the N-terminal acetyltransferase A (NatA) complex.

Subunit / interactions. Component of the N-terminal acetyltransferase A (NatA) complex composed of NAA11 and NAA15. Interacts with HIF1A.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Present in several cell lines, with highest levels in MCF-7 cells (at protein level).

Similarity. Belongs to the acetyltransferase family. ARD1 subfamily.

RefSeq proteins (1): NP_116082* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000182	GNAT_dom	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR045047	Ard1-like	Family

Pfam: PF00583

Catalyzed reactions (Rhea), 6 shown:

• N-terminal glycyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetylglycyl-[protein] + CoA + H(+) (RHEA:50496)
• N-terminal L-alanyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-alanyl-[protein] + CoA + H(+) (RHEA:50500)
• N-terminal L-seryl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-seryl-[protein] + CoA + H(+) (RHEA:50504)
• N-terminal L-valyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-valyl-[protein] + CoA + H(+) (RHEA:50508)
• N-terminal L-cysteinyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-cysteinyl-[protein] + CoA + H(+) (RHEA:50512)
• N-terminal L-threonyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-threonyl-[protein] + CoA + H(+) (RHEA:50516)

UniProt features (10 total): compositionally biased region 3, region of interest 2, sequence variant 2, chain 1, domain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BSU3-F1	80.62	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 186

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 64 (showing top): GOBP_N_TERMINAL_PROTEIN_AMINO_ACID_ACETYLATION, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_ACETYLATION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, GOBP_PROTEIN_ACYLATION, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, MODULE_47, GOBP_N_TERMINAL_PROTEIN_AMINO_ACID_MODIFICATION, chr4q21, GOCC_TRANSFERASE_COMPLEX, GOCC_N_TERMINAL_PROTEIN_ACETYLTRANSFERASE_COMPLEX, GOMF_ACETYLTRANSFERASE_ACTIVITY, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_N_ACYLTRANSFERASE_ACTIVITY, GOMF_N_ACETYLTRANSFERASE_ACTIVITY

GO Biological Process (1): N-terminal protein amino acid acetylation (GO:0006474)

GO Molecular Function (8): protein-N-terminal amino-acid acetyltransferase activity (GO:0004596), protein-N-terminal-alanine acetyltransferase activity (GO:0008999), protein N-terminal-serine acetyltransferase activity (GO:1990189), protein-N-terminal-glutamate acetyltransferase activity (GO:1990190), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), acyltransferase activity, transferring groups other than amino-acyl groups (GO:0016747)

GO Cellular Component (9): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), centrosome (GO:0005813), cytosol (GO:0005829), cilium (GO:0005929), NatA complex (GO:0031415), ciliary basal body (GO:0036064), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-N-terminal amino-acid acetyltransferase activity	3
cellular anatomical structure	3
cytoplasm	2
intracellular membrane-bounded organelle	2
microtubule organizing center	2
protein acetylation	1
N-terminal protein amino acid modification	1
protein maturation	1
protein N-acetyltransferase activity	1
binding	1
catalytic activity	1
transferase activity	1
acyltransferase activity	1
nuclear lumen	1
intracellular anatomical structure	1
endomembrane system	1
centriole	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
N-terminal protein acetyltransferase complex	1
cilium	1

Protein interactions and networks

STRING

672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAA11	NAA16	Q6N069	870
NAA11	NAA15	Q9BXJ9	846
NAA11	NAA50	Q9GZZ1	714
NAA11	NAA40	Q86UY6	708
NAA11	NAA35	Q5VZE5	624
NAA11	NAA60	Q9H7X0	611
NAA11	NAA25	Q14CX7	564
NAA11	HYPK	Q9NX55	503
NAA11	PSKH2	Q96QS6	491
NAA11	NAA30	Q147X3	472
NAA11	TEX44	Q53QW1	467
NAA11	CFAP20DC	Q6ZVT6	444
NAA11	PLEKHN1	Q494U1	431
NAA11	ZNF396	Q96N95	418
NAA11	PDHA2	P29803	402

IntAct

45 interactions, top by confidence:

A	B	Type	Score
NAA10	NAA16	psi-mi:“MI:0914”(association)	0.710
NAA11	CDCA5	psi-mi:“MI:0915”(physical association)	0.560
CREBRF	NAA11	psi-mi:“MI:0915”(physical association)	0.560
ZBTB14	NAA11	psi-mi:“MI:0915”(physical association)	0.560
TOM1	NAA11	psi-mi:“MI:0915”(physical association)	0.560
KIFAP3	NAA11	psi-mi:“MI:0915”(physical association)	0.560
ACOT12	NAA11	psi-mi:“MI:0915”(physical association)	0.560
AP2M1	NAA11	psi-mi:“MI:0915”(physical association)	0.560
ZNF202	NAA11	psi-mi:“MI:0915”(physical association)	0.560
CDCA5	NAA11	psi-mi:“MI:0915”(physical association)	0.560
CDC25A	NAA11	psi-mi:“MI:0915”(physical association)	0.560
MTARC1	NAA11	psi-mi:“MI:0915”(physical association)	0.560
EHMT2	NAA11	psi-mi:“MI:0915”(physical association)	0.560
BAALC	NAA11	psi-mi:“MI:0915”(physical association)	0.560
NAA15	NAA11	psi-mi:“MI:0915”(physical association)	0.560
NAA11	NAA16	psi-mi:“MI:0915”(physical association)	0.560
	NAA11	psi-mi:“MI:0192”(acetylation reaction)	0.440
RIN2	NAA10	psi-mi:“MI:0914”(association)	0.350
NAA11	DVL2	psi-mi:“MI:0914”(association)	0.350
FMNL3	UBXN7	psi-mi:“MI:0914”(association)	0.350
NAA11	CREBRF	psi-mi:“MI:0915”(physical association)	0.000
NAA11	EHMT2	psi-mi:“MI:0915”(physical association)	0.000
NAA11	TOM1	psi-mi:“MI:0915”(physical association)	0.000
NAA11	KIFAP3	psi-mi:“MI:0915”(physical association)	0.000
NAA11	ZBTB14	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (64): NAA11 (Affinity Capture-MS), NAA11 (Synthetic Lethality), NAA11 (Two-hybrid), NAA11 (Two-hybrid), NAA11 (Two-hybrid), AP2M1 (Two-hybrid), CDC25A (Two-hybrid), CREBRF (Two-hybrid), BAALC (Two-hybrid), ZNF202 (Two-hybrid), ACOT12 (Two-hybrid), MARC1 (Two-hybrid), ZBTB14 (Two-hybrid), EHMT2 (Two-hybrid), NAA11 (Affinity Capture-MS)

ESM2 similar proteins: A0A2R8QFQ6, A4IFE4, A9X1D0, B0VX69, B5FW36, C1FXW2, D1LYT2, D3Z7P3, G3MWR8, G3V6U9, O13016, O46411, O88508, O94925, O95544, P13264, P18031, P18507, P20417, P21548, P22723, P35790, P35821, P41227, P47870, P58058, Q01134, Q0VAM2, Q14722, Q1LZ53, Q2KI14, Q3ULA2, Q3UX61, Q4V8K3, Q4W5Z4, Q5RC04, Q5SRY7, Q5ZML9, Q6ZPR4, Q7RTP6

Diamond homologs: O61219, O74457, P07347, P36416, P41227, P61599, P61600, Q03503, Q05885, Q06504, Q2KI14, Q2PFM2, Q3UX61, Q4JBG0, Q4V8K3, Q58925, Q58ED9, Q6P632, Q7ZXR3, Q8SSN5, Q976C3, Q980R9, Q9BSU3, Q9FKI4, Q9QY36, Q9UTI3, A1R8Y2, A8E5V7, A9WNI5, C0ZP17, C1ATC6, C3PIU4, C6WPR7, D0L3V5, D2S4P5, D6Y4C5, E0CYC6, O05517, O34376, O74311

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	33
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

119 predictions. Top by Δscore:

Variant	Effect	Δscore
4:79325171:AATAC:A	donor_loss	1.0000
4:79325172:ATACC:A	donor_loss	1.0000
4:79325173:TACC:T	donor_loss	1.0000
4:79325174:A:AT	donor_loss	1.0000
4:79325175:CCT:C	donor_loss	1.0000
4:79325170:GAATA:G	donor_loss	0.9900
4:79325219:T:TA	donor_gain	0.9800
4:79320325:C:CT	acceptor_gain	0.9700
4:79325179:AAG:A	donor_gain	0.9600
4:79317790:TG:T	acceptor_gain	0.9500
4:79317792:C:CC	acceptor_gain	0.9400
4:79325206:G:C	donor_gain	0.9400
4:79317792:CTGTT:C	acceptor_gain	0.9100
4:79317795:T:TC	acceptor_gain	0.9100
4:79317789:ATG:A	acceptor_gain	0.9000
4:79317790:TGC:T	acceptor_loss	0.9000
4:79317791:GC:G	acceptor_loss	0.9000
4:79317789:ATGCT:A	acceptor_gain	0.8900
4:79317790:TGCTG:T	acceptor_gain	0.8900
4:79317791:GCTGT:G	acceptor_gain	0.8900
4:79325215:G:C	donor_gain	0.8600
4:79317795:T:C	acceptor_gain	0.8500
4:79317788:AATG:A	acceptor_gain	0.8300
4:79325541:T:TA	donor_gain	0.8200
4:79317793:T:A	acceptor_gain	0.8100
4:79325180:A:C	donor_gain	0.8100
4:79319805:CGAAT:C	donor_gain	0.8000
4:79325210:T:A	donor_gain	0.8000
4:79317788:AATGC:A	acceptor_gain	0.7800
4:79317787:AAATG:A	acceptor_gain	0.7700

AlphaMissense

1528 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:79325543:C:A	R112M	1.000
4:79325469:A:G	Y137H	0.999
4:79325494:A:C	F128L	0.999
4:79325494:A:T	F128L	0.999
4:79325496:A:G	F128L	0.999
4:79325542:C:A	R112S	0.999
4:79325542:C:G	R112S	0.999
4:79325543:C:G	R112T	0.999
4:79325546:A:T	V111D	0.999
4:79325552:A:G	L109P	0.999
4:79325609:A:G	L90P	0.999
4:79325658:A:G	S74P	0.999
4:79325669:C:T	G70D	0.999
4:79325717:C:T	G54D	0.999
4:79325744:G:T	A45D	0.999
4:79325824:G:C	N18K	0.999
4:79325824:G:T	N18K	0.999
4:79325466:A:G	Y138H	0.998
4:79325495:A:G	F128S	0.998
4:79325516:A:G	L121P	0.998
4:79325552:A:T	L109Q	0.998
4:79325633:C:G	R82P	0.998
4:79325648:A:T	V77E	0.998
4:79325651:G:T	A76D	0.998
4:79325718:C:G	G54R	0.998
4:79325745:C:G	A45P	0.998
4:79325766:A:G	W38R	0.998
4:79325766:A:T	W38R	0.998
4:79325778:G:C	H34D	0.998
4:79325790:A:G	Y30H	0.998

dbSNP variants (sampled 300 via entrez): RS1000039454 (4:79161882 C>T), RS1000047267 (4:79279487 C>T), RS1000057777 (4:79267581 A>G), RS1000108203 (4:79267125 T>G), RS1000118580 (4:79281756 G>C), RS1000122636 (4:79260841 A>G), RS1000128803 (4:79173047 C>A), RS1000142822 (4:79168906 G>A), RS1000149771 (4:79217782 A>G), RS1000152447 (4:79261284 T>C,G), RS1000155745 (4:79325666 T>C), RS1000184719 (4:79266634 A>G,T), RS1000193051 (4:79168643 A>G,T), RS1000202617 (4:79236494 A>G), RS1000233798 (4:79200367 T>C,G)

Disease associations

OMIM: gene MIM:619432 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): autism spectrum disorder (MONDO:0005258)

Orphanet (1): NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST003059_9	Parkinson’s disease	1.000000e-06
GCST007325_49	General risk tolerance (MTAG)	5.000000e-08
GCST007576_213	Chronotype	4.000000e-08
GCST009600_18	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	4.000000e-09
GCST010002_9	Refractive error	2.000000e-65
GCST011768_14	Schizophrenia	3.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, decreases methylation, affects methylation	2
FR900359	increases phosphorylation	1
butyraldehyde	increases expression	1
Acetaminophen	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
NCT04623398	PHASE3	COMPLETED	Effect of Lithium in Patients With Autism Spectrum Disorder and Phelan-McDermid Syndrome (SHANK3 Haploinsufficiency)
NCT04725383	PHASE3	TERMINATED	Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders
NCT05212493	PHASE3	COMPLETED	The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder
NCT05361707	PHASE3	UNKNOWN	Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05439616	PHASE3	COMPLETED	Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD
NCT06229210	PHASE3	RECRUITING	Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder